Gedatolisib Combination Treatment for Advanced Hormone

Gedatolisib Combination Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
83%48%14%Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25May 21 • YES 24.9%May 22 • YES 28.9%May 23 • YES 65.9%May 24 • YES 70.9%May 25 • YES 71.5%
Celcuity Inc ($CELC)
No stock closeNo stock close$128.1$119.8$111.6Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25Apr 21 • CELC $126.1Apr 22 • CELC $122.4Apr 23 • CELC $113.6Apr 24 • CELC $121.0Apr 27 • CELC $125.7Apr 28 • CELC $120.1Apr 29 • CELC $119.0Apr 30 • CELC $121.4May 1 • CELC $125.7
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Resolved Date
5/1/26
Study Completion
12/31/26
Sponsor
Celcuity Inc
Ticker
$CELC
Type
Phase 3
Trial Status
Active, not recruiting
Trial Size
701
NCT
NCT05501886
Trial Description
Gedatolisib combinations are being tested after prior CDK4/6 and aromatase inhibitor therapy, measuring time before advanced hormone receptor-positive, HER2-negative breast cancer worsens.